Arovella Therapeutics Limited (ASX: ALA) and Imugene (ASX: IMU) have announced the successful outcome of in vitro experiments conducted as part of their research collaboration.

They are now progressing to the next phase of testing, involving in vivo trials of the ALA/IMU drug combination.

Results from the second stage of testing are expected to be available mid-2023.

This collaboration opens potential new therapeutic targets for ALA-101 in solid tumours, which represent 90% of diagnosed cancer cases and make up a market worth US$210 billion.